LifeMD, Inc. (LFMD) Q2 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents mixed signals: strong telehealth revenue growth and strategic partnerships are positive, but concerns arise from fluctuating customer acquisition costs and guidance reduction related to the RexMD business. The Q&A reveals management's evasiveness on certain metrics, which can create uncertainty. Despite positive new initiatives and raised guidance for 2025, the immediate impact is tempered by operational challenges and lack of clear answers on key metrics, resulting in a neutral sentiment.
Key Financial Performance
Consolidated Revenue $62.2 million, a 23% year-over-year increase. The growth was driven by a 30% increase in telehealth revenue and strong performance in the WorkSimpli business.
Telehealth Revenue $48.6 million, a 30% year-over-year increase. This growth was attributed to the strong performance of the core telehealth business.
WorkSimpli Adjusted EBITDA $3.7 million, a 119% year-over-year increase. The growth was due to strong bottom-line performance.
Telehealth Adjusted EBITDA $3.4 million, a 560% year-over-year increase. This was driven by the strong performance of the telehealth business.
Gross Margin 88%, a decline of 210 basis points year-over-year. The decline was due to a higher allocation rate of physician costs to COGS driven by higher utilization.
Gross Profit $54.5 million, a 19% year-over-year increase. This was driven by the overall revenue growth.
GAAP Net Loss $2.9 million, compared to $7.7 million in the prior year. The improvement was due to better overall financial performance.
Adjusted EBITDA $7.1 million, compared to $2.2 million in the prior year. This improvement reflects better financial performance across the business.
Telehealth Subscriber Growth 16% year-over-year increase to over 297,000 subscribers. This growth was driven by the strong performance of the telehealth business.
WorkSimpli Active Subscribers 149,000, a 6% year-over-year decline. The decline was due to a focus on acquiring higher LTV customers to maximize profitability.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Behavioral Health Offering: Launched a nationwide behavioral health program focused on adult anxiety and depression, addressing unmet patient needs. Expected to scale in Q4 and contribute to 2026 results.
Women's Health Program: Upcoming launch of a holistic women's health program addressing menopause, hormone therapy, and bone health. Expected to scale in Q4 and contribute to 2026 results.
LifeMD+ Membership Program: Launched a premium membership program offering personalized care, same-day prescription renewals, lab testing, and more. Currently attracting nearly 50 new patient sign-ups per day.
Weight Management Program: Continued strong performance with over 400 new patient sign-ups per day. Expanded access to oral generic weight loss medications and added liraglutide as a covered option.
RexMD Brand: Adjusted marketing and product strategies to address elevated customer acquisition costs in the ED market. Early Q3 data shows improvement.
AI Integration: Integrated AI into operations to streamline administrative tasks, improve patient outcomes, and enhance provider productivity.
Debt Repayment: Fully repaid senior venture debt, saving $1.1 million in future interest payments and making the business debt-free.
Platform Diversification: Expanded into behavioral health and women's health, addressing large underserved markets.
Enterprise Partnerships: Focused on collaborations to introduce significant new patient volume into LifeMD+ and specialty care programs.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Weight Management Refund Rates: Higher-than-anticipated refund rates due to patients lacking insurance coverage or being unable to afford out-of-pocket costs for branded therapies. This creates a near-term headwind for the weight management segment.
RexMD Customer Acquisition Costs: Temporarily elevated customer acquisition costs in the competitive ED market, impacting the RexMD business performance in the second quarter.
Revenue and EBITDA Guidance Revision: The company revised its 2025 revenue and adjusted EBITDA guidance downward, reflecting challenges in achieving prior growth expectations.
Telehealth Gross Margin Decline: Gross margin declined by 210 basis points due to higher allocation of physician costs to COGS driven by increased utilization.
WorkSimpli Subscriber Contraction: Active subscribers for WorkSimpli contracted by 6%, attributed to a focus on acquiring higher LTV customers, which may limit short-term growth.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Weight Management Program: LifeMD expects the majority of new patients to be on insurance-covered GLP-1 therapy, affordable cash-based therapy, or oral prescription therapies for weight loss by year-end. The company is enhancing its patient intake process to include real-time benefit verification and expanding access to oral generic weight loss medications and liraglutide. These efforts aim to improve patient experience and conversion rates.
RexMD Brand: LifeMD anticipates a return to healthier customer acquisition levels in the third quarter after adjusting marketing and product strategies. The company is broadening offerings into hormone replacement therapy, personalized compounded treatments for ED and hair loss, and additional men's health categories, which are expected to contribute to future growth.
Behavioral Health Offering: The nationwide behavioral health program focused on adult anxiety and depression is expected to scale in Q4 2025 and become accretive to 2026 results. This program addresses significant unmet patient needs and complements existing offerings.
Women's Health Program: The holistic women's health program addressing menopause, hormone therapy, and bone health is expected to launch at the end of Q3 2025, scale in Q4, and become accretive to 2026 results. This program targets a large, underserved market of women aged 45 and older.
LifeMD+ Membership Program: The LifeMD+ membership program, offering personalized patient care and additional benefits, is gaining traction with nearly 50 new patient sign-ups per day. It is expected to drive long-term patient relationships, retention, and preventative care.
Financial Guidance for 2025: LifeMD revised its 2025 consolidated revenue guidance to $250 million-$255 million (from $268 million-$275 million) and telehealth revenue guidance to $195 million-$200 million (from $208 million-$213 million). Adjusted EBITDA guidance was revised to $27 million-$29 million (from $31 million-$33 million). Telehealth stand-alone adjusted EBITDA guidance is now $14 million-$16 million (from $21 million).
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you speak more about the insurance opportunity where you are right now? For example, how many states you're in? What portions of members are you taking insurance for? And what does the margin profile look like for those members compared to cash pay?
A:LifeMD is contracted with over 100 insurance plans across 40 states, covering just under 80 million lives. This is expected to double by the end of the year. The insurance business is currently a small percentage of the overall business but is expected to scale considerably by 2026. Unit economics for insurance-sponsored patients are strong and can result in better LTVs compared to cash pay patients, especially in areas like women's health and weight management.
Q:Any comments on your relationships with Novo and Lilly?
A:The integrations with Lilly Direct and NovoCare are in place, and LifeMD continues to see a greater number of patients accessing self-pay branded therapies through these integrations.
Q:Can you give more color on what was going on with the rep customer acquisition costs? Was the step-up in customer acquisition cost due to pricing or changes in sales from leads?
A:Customer acquisition costs (CACs) fluctuated during the quarter, with increases of 15%-25% sequentially at times. This led to reduced volume and impacted acquisition revenue and related subscription revenue. LifeMD has taken proactive actions to address this, and CACs have returned to historical levels. The company is diversifying its business to better manage such disruptions in the future.
Q:Do you mean that you're having tighter control on your acquisition spend, or do you think sales will return to historical levels?
A:LifeMD has seen improvements in acquisitions per day, approaching historical levels, and CACs have returned to historical levels. The company acknowledges it could have acted faster to address the issue but feels confident about the current state of the business.
Q:Is the full-year guidance reduction related to the RexMD business, and what impact will this have on Q3 and Q4?
A:The majority of the guidance reduction is related to the RexMD business, with a small proportion due to higher refund rates in the weight management segment. Sales per day are currently at 85%-90% of historical levels, and the guidance assumes no complete rebound in RexMD.
Q:How should we think about marketing and spend associated with the LifeMD+ offering?
A:Marketing spend for LifeMD+ is included in the plan, with a measured approach to balance profitability and growth. Currently, about 50 new sign-ups are being added daily, and the company aims to scale this significantly.
Q:What percentage of patients with insurance coming in for GLP-1s are being approved for coverage?
A:LifeMD does not have an exact percentage but expects 75% of new patients to be on either insurance-covered GLP-1 medications or self-pay products by the end of the year. The company is also launching more generic oral therapy options, which could account for 10%-20% of the business.
Q:Can you provide an update on the recent launch in behavioral health? How many initial subscribers have you seen, and what revenue contribution is expected in the back half of the year?
A:The behavioral health program is live across all 50 states, and patients are being onboarded daily. The focus is currently on testing and refining processes, with scaling expected in the next 30-60 days.
Q:How is the initial launch of your Medicare fee-for-service initiative progressing? Have you expanded to 49 states and 60 million beneficiaries as expected?
A:The Medicare fee-for-service initiative is on track to expand to 49 states by the end of the year. Structural adjustments with the medical group delayed scaling, but the program is expected to scale in the back half of the year.
Q:What is the refund rate policy with your customers, and did anything drive higher refund rates this quarter?
A:LifeMD has a liberal refund policy, offering full refunds if patients do not receive treatment or insurance coverage. Higher refund rates were driven by patients opting for cheaper alternatives to branded therapies. Collaborations with Lilly and Novo did not directly affect refund rates.
Q:Is LifeMD still offering personalized GLP-1s, and what percentage of the weight management subscriber base is on those?
A:LifeMD offers personalized GLP-1s in certain cases where clinically appropriate. The exact percentage of weight management subscribers on personalized GLP-1s was not disclosed.
Q:What is the number of subscribers using weight management versus telehealth, and what are the attrition rates?
A:Weight management accounts for 30%-35% of active subscribers, with RexMD being the largest segment. About one-third of cohorts are retained after 12 months, with higher retention among those on therapy.
Q:Is insurance coverage the most meaningful differentiating feature for LifeMD against competitors?
A:Insurance coverage is a key differentiator, along with LifeMD's ability to offer high-quality synchronous care across all 50 states. The platform allows patients to use insurance or Medicare and choose between asynchronous or synchronous care.
Q:Review of Unclear Management Responses
A:Management avoided providing direct answers to the following: 1) The exact percentage of patients with insurance coverage for GLP-1s. 2) The number of initial subscribers for the behavioral health program. 3) The percentage of weight management subscribers on personalized GLP-1s.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AI
Benathen Chief
Capital Markets
GLP therapy
Health
Human
Inc Research
LLC Research
Research Division
RexMD
Schreiber Chairman
WorkSimpli
adult
care gap
customer acquisition
debt
hair loss
market opportunity
patient sign
perimenopausal
platform weight
prescription weight
process
rate patient
refund rate
sign ups
stage
task
telehealth increase
term outlook
therapy prescription
ups day
weight program
woman care
LFMD Transcript
LifeMD, Inc. (LFMD) Q1 2026 Earnings Call Transcript
Unknown5-6
The earnings call reveals a mixed picture: increased losses and a decline in revenue, yet strong cash position and strategic partnerships with Novo and Lilly. The Q&A highlights promising insurance-supported programs and strategic shifts, but concerns about revenue guidance and unclear management responses persist. With no market cap data, the lack of strong catalysts and mixed financial indicators suggest a neutral stock price movement in the short term.
LifeMD, Inc. (LFMD) Q4 2025 Earnings Call Transcript
Positive3-9
The earnings call highlights strong financial performance with revenue and EBITDA growth, no debt, and a positive cash position. The Q&A reveals robust demand for the Wegovy pill, promising initial retention rates, and strategic investments in growth areas like women's health. While management was vague on some specifics, the overall sentiment remains positive due to strong financial metrics, optimistic guidance, and strategic partnerships, despite some uncertainties.
LifeMD, Inc. (LFMD) Q3 2025 Earnings Call Transcript
Unknown11-17
The earnings call reveals several concerns: a decline in weight management revenue, reduced financial guidance, and margin pressures due to shifts in business mix. Although there is optimism for 2026 and some positive developments like insurance coverage and new product lines, these are long-term prospects. The immediate financial outlook is weakened by the revised guidance and margin erosion, leading to a likely negative market reaction in the short term.
LifeMD, Inc. (LFMD) Q2 2025 Earnings Call Transcript
Unknown8-5
The earnings call presents mixed signals: strong telehealth revenue growth and strategic partnerships are positive, but concerns arise from fluctuating customer acquisition costs and guidance reduction related to the RexMD business. The Q&A reveals management's evasiveness on certain metrics, which can create uncertainty. Despite positive new initiatives and raised guidance for 2025, the immediate impact is tempered by operational challenges and lack of clear answers on key metrics, resulting in a neutral sentiment.
LFMD Slides
LFMD Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
